MedDataX Logo

Evaluation of the Effect of Telmisartan on Blood Pressure Control of High Risk Patients

NCT ID: NCT01108809

Last Updated: 2014-03-28

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

295 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study is designed to evaluate the effect of treatment with Micardis/MicardisPlus on blood pressure and its ability to reduce different indicated cardiovascular risk scores. The study will also evaluate the current antihypertensive treatment pattern in the daily practice among the patient population at increased cardiovascular risk.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluation of the Effect of Telmisartan (Micardis® 80 mg/ MicardisPlus® 80/12.5 mg) on Blood Pressure and Cardiovascular Risk Factor Index in High Risk Hypertensive Patients

NCT00904371

Hypertension Cardiovascular Diseases
COMPLETED

Study of Hypertensive Population Under Treatment With Telmisartan in Real Clinical Conditions With the Goal to Control Early Morning Blood Pressure Rise

NCT00946829

Hypertension
COMPLETED

Effectiveness of MICARDIS® (Telmisartan) on Blood Pressure Control and Quality of Live in Patients With Essential Hypertension

NCT02242370

Hypertension
COMPLETED PHASE4

Telmisartan (Micardis) and Amlodipine (Norvasc) - Factorial Design Study for the Treatment of Hypertension

NCT00281580

Hypertension
COMPLETED PHASE3

Micardis® in Patients With Essential Hypertension

NCT02187705

Hypertension
COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with arterial hypertension

Telmisartan or Telmisartan and Hydrochlorthiazide

Intervention Type DRUG

Telmisartan 80mg +/- Hydrochlorthiazide 12.5mg or 25mg

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Telmisartan or Telmisartan and Hydrochlorthiazide

Telmisartan 80mg +/- Hydrochlorthiazide 12.5mg or 25mg

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* diagnosis of essential arterial hypertension (BP\>140/90 mm HG or BP\>130/80 mm Hg for diabetic patients)
* at least one additional cardiovascular risk factor and/or known single or multiple end organ damage and/or previous cardiovascular disease

Exclusion Criteria

* hypersensitivity to the active substance or to any of the excipients in any ACE inhibitor or angiotensin receptor blocker (ARB) available on the local market, as prescribed in the SPC
* pregnancy and lactation
* diseases involving biliary obstruction
* severe liver impairment
* severe hypertension
* malignant hypertension
* secondary hypertension
* patients age under 18 years
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Boehringer Ingelheim

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Boehringer Ingelheim

Role: STUDY_CHAIR

Boehringer Ingelheim

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Boehringer Ingelheim Investigational Site 1

Arad, , Romania

Site Status

Boehringer Ingelheim Investigational Site 5

Bacau, , Romania

Site Status

Boehringer Ingelheim Investigational Site 6

Baia Mare, , Romania

Site Status

Boehringer Ingelheim Investigational Site 9

Brasov, , Romania

Site Status

Boehringer Ingelheim Investigational Site 8

Brăila, , Romania

Site Status

Boehringer Ingelheim Investigational Site 10

Bucharest, , Romania

Site Status

Boehringer Ingelheim Investigational Site 11

Bucharest, , Romania

Site Status

Boehringer Ingelheim Investigational Site 12

Bucharest, , Romania

Site Status

Boehringer Ingelheim Investigational Site 13

Bucharest, , Romania

Site Status

Boehringer Ingelheim Investigational Site 14

Bucharest, , Romania

Site Status

Boehringer Ingelheim Investigational Site 15

Bucharest, , Romania

Site Status

Boehringer Ingelheim Investigational Site 16

Bucharest, , Romania

Site Status

Boehringer Ingelheim Investigational Site 17

Bucharest, , Romania

Site Status

Boehringer Ingelheim Investigational Site 18

Bucharest, , Romania

Site Status

Boehringer Ingelheim Investigational Site 19

Bucharest, , Romania

Site Status

Boehringer Ingelheim Investigational Site 20

Bucharest, , Romania

Site Status

Boehringer Ingelheim Investigational Site 21

Bucharest, , Romania

Site Status

Boehringer Ingelheim Investigational Site 22

Bucharest, , Romania

Site Status

Boehringer Ingelheim Investigational Site 23

Buzău, , Romania

Site Status

Boehringer Ingelheim Investigational Site 4

Campulung Muscel, , Romania

Site Status

Boehringer Ingelheim Investigational Site 42

Carei, , Romania

Site Status

Boehringer Ingelheim Investigational Site 24

Călăraşi, , Romania

Site Status

Boehringer Ingelheim Investigational Site 26

Cluj-Napoca, , Romania

Site Status

Boehringer Ingelheim Investigational Site 27

Cluj-Napoca, , Romania

Site Status

Boehringer Ingelheim Investigational Site 28

Cluj-Napoca, , Romania

Site Status

Boehringer Ingelheim Investigational Site 29

Constanța, , Romania

Site Status

Boehringer Ingelheim Investigational Site 31

Craiova, , Romania

Site Status

Boehringer Ingelheim Investigational Site 2

Curtea de Argeş, , Romania

Site Status

Boehringer Ingelheim Investigational Site 38

Drobeta-Turnu Severin, , Romania

Site Status

Boehringer Ingelheim Investigational Site 32

Galati, , Romania

Site Status

Boehringer Ingelheim Investigational Site 34

Iași, , Romania

Site Status

Boehringer Ingelheim Investigational Site 35

Iași, , Romania

Site Status

Boehringer Ingelheim Investigational Site 36

Iași, , Romania

Site Status

Boehringer Ingelheim Investigational Site 37

Iași, , Romania

Site Status

Boehringer Ingelheim Investigational Site 7

Oradea, , Romania

Site Status

Boehringer Ingelheim Investigational Site 3

Piteşti, , Romania

Site Status

Boehringer Ingelheim Investigational Site 40

Ploieşti, , Romania

Site Status

Boehringer Ingelheim Investigational Site 41

Ploieşti, , Romania

Site Status

Boehringer Ingelheim Investigational Site 49

Râmnicu Vâlcea, , Romania

Site Status

Boehringer Ingelheim Investigational Site 25

Reşiţa, , Romania

Site Status

Boehringer Ingelheim Investigational Site 33

Slobozia, , Romania

Site Status

Boehringer Ingelheim Investigational Site 43

Suceava, , Romania

Site Status

Boehringer Ingelheim Investigational Site 30

Târgovişte, , Romania

Site Status

Boehringer Ingelheim Investigational Site 39

Târgu Mureş, , Romania

Site Status

Boehringer Ingelheim Investigational Site 44

Timișoara, , Romania

Site Status

Boehringer Ingelheim Investigational Site 45

Timișoara, , Romania

Site Status

Boehringer Ingelheim Investigational Site 46

Timișoara, , Romania

Site Status

Boehringer Ingelheim Investigational Site 47

Timișoara, , Romania

Site Status

Boehringer Ingelheim Investigational Site 48

Tulcea, , Romania

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Romania

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

502.592

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Efficacy and Safety of Chronic Administration of Telmisartan as Monotherapy or in Combination With Hydrochlorothiazide or Other Antihypertensive Medications in Patients With Mild to Moderate Hypertension
NCT02177422 COMPLETED PHASE3
Post-Marketing Surveillance of Micardis® (Telmisartan) in Patients With Hypertension
NCT02242838 COMPLETED
Evaluation of Efficacy and Tolerability of Micardis® / MicardisPlus® Under Usual Daily-practice Prescribing in Patients With Hypertension
NCT02242383 COMPLETED
Study to Evaluate the Trough and Peak Effect of Once Daily Telmisartan 80 mg/Hydrochlorothiazide 12.5 mg (Micardis Plus) by Ambulatory Blood Pressure Monitoring (ABPM) in Patients With Mild to Moderate Essential Hypertension
NCT00257491 COMPLETED PHASE3
A Bioequivalence Study Between Telmione 80 mg and Micardis 80 mg in Healthy Adult Volunteers
NCT05223101 UNKNOWN PHASE1
Additional Effect of A Life Style Program on Antihypertensive Treatment With Telmisartan
NCT01108796 COMPLETED
Investigating the Effect of Telmisartan (Micardis®) on the Average 24h Blood Pressure of Therapy-naive and Therapy-experienced Patients
NCT00879411 COMPLETED
Relative Bioavailability of Telmisartan and HCTZ in Two Experimental Formulations Compared to the Standard Formulation Telmisartan and HCTZ in Healthy Female and Male Subjects
NCT02262572 COMPLETED PHASE1
A Trial Comparing MICARDIS® (Telmisartan) and COZAAR® (Losartan) in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring (ABPM)
NCT02200640 COMPLETED PHASE4
Nice Morning- Safety and Efficacy Observational Study of Telmisartan in Hypertensive Patients in Multicenters
NCT00615108 COMPLETED
A Prospective, Randomised, Double-blind, Double-dummy, Forced-titration, Multicentre, Parallel Group, One Year Treatment Trial to Compare Telmisartan (MICARDIS) 80 mg Versus Losartan (COZAAR) 100 mg, in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy (AMADEO Study)
NCT00168857 COMPLETED PHASE4
Post Marketing Surveillance (PMS) Study to Assess Safety and Efficacy of Micardis in Patients With Essential Hypertension
NCT02245464 COMPLETED
A Randomized, Double-blind, Parallel-group Assessment of the Safety and Efficacy of Telmisartan 40mg Plus Hydrochlorothiazide 12.5mg (Micardis Plus) in Comparison With Losartan 50mg Plus Hydrochlorothiazide 12.5mg in Taiwanese Patients With Mild to Moderate Hypertension
NCT00133185 COMPLETED PHASE3
Micardis® / MicardisPlus® Program for Therapy Optimization With Telmisartan in Cardiovascular Diseases (PROTEKT)
NCT02262637 COMPLETED
An Observational Study to Investigate the Efficacy, Safety, Tolerability and the Effect on Quality of Life of Telmisartan (Micardis) and Telmisartan With HCTZ (Micardis Plus) in Patients With Hypertension
NCT00904215 COMPLETED
Pharmacokinetics of Telmisartan Alone and in Combination With Amlodipine in Healthy Volunteers
NCT02259816 COMPLETED PHASE1
A Trial Comparing MICARDIS® (Telmisartan) and COZAAR® / LORZAAR® (Losartan) in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring (ABPM)
NCT02200653 COMPLETED PHASE4
PROBE Investigation of the Safety & Efficacy of Telmisartan (Micardis®) vs Ramipril (Altace®) Using ABPM in HTN
NCT00274599 COMPLETED PHASE4
Telmisartan Versus Amlodipine in Patients With Mild-to-Moderate Hypertension
NCT02177409 COMPLETED PHASE3
Telmisartan+HCTZ (Hydrochlorothiazide), Hypertension
NCT00659607 COMPLETED
A Bioequivalence Study Between Telmione Plus 80/12.5mg and Micardis Plus 80/12.5 mg in Healthy Adult Volunteers
NCT05040880 COMPLETED PHASE1
Telmisartan (Micardis) and Ramipril (Altace) - Factorial Design Study for the Treatment of Hypertension
NCT00281593 COMPLETED PHASE3
Efficacy and Safety of the Angiotensin II Receptor Antagonist Micardis® (Telmisartan) or Hydrochlorothiazide in the Management of Patients With Isolated Systolic Hypertension (ISH)
NCT02175355 COMPLETED PHASE3
J-TARGET,Japanese Telmisartan Study for Antihypertensive Good Effect in Long Term Observation
NCT00659581 COMPLETED
TELSYS - TELmisartan Effectiveness in Isolated SYStolic Hypertension Versus Systolic/Diastolic Hypertension Patients Aged 55 or Older
NCT02242877 COMPLETED